Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504082 | 0.89 | CASR (0.39) | CASRADRB2ADRB1 | |
| SCHEMBL5500953 | 0.78 | CASR (0.46) | CASRDPP4ADRB2ADRB1KDM4E | |
| SCHEMBL6009423 | 0.74 | DPP4 (0.44) | CASRDPP4ADRB2ADRB1KDM4E | |
| SCHEMBL6009449 | 0.74 | CASR (0.44) | CASRDPP4ADRB2ADRB1KDM4E | |
| SCHEMBL5503326 | 0.72 | ADRB2 (0.33) | ADRB2ADRB1ADRB3 | |
| SCHEMBL6009992 | 0.69 | HTT (0.35) | ADRB2ADRB1KDM4EADRB3 | |
| SCHEMBL10087170 | 0.68 | CASR (0.44) | CASRDPP4ADRB2ADRB1KDM4E | |
| SCHEMBL5503668 | 0.68 | CASR (0.39) | CASRADRB2ADRB1ADRB3 | |
| SCHEMBL14383005 | 0.67 | CASR (0.80) | CASRADRB2ADRB1ADRB3 | |
| SCHEMBL5503681 | 0.67 | MMP2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | CASR 3333/4885DPP4 1442/4885ADRB2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.